Genetic variant may help predict ovarian cancer risk

Share this content:
Doctors can predict the risk of developing ovarian cancer using a genetic marker, according to a study published in Cancer Research (2010 Jul 20. [Epub ahead of print]).

The study researchers from Yale Cancer Center first searched for a variant of the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) oncogene among ovarian cancer patients and found that one in four had the gene variant, compared to 6% of the general population. Researchers confirmed their discovery that the KRAS-variant was a genetic marker of ovarian cancer risk when they studied women with ovarian cancer who also had evidence of a hereditary breast and ovarian cancer syndrome.

The results of the study revealed that the KRAS-variant was present in 61% of ovarian cancer patients with a family history of breast and ovarian cancer. In addition, six out of 10 women without other known genetic markers of ovarian cancer risk had the KRAS-variant. Researchers suggested that the marker may be a new sign of ovarian cancer risk for women with a family history of ovarian cancer.

“For many women out there with a strong family history of ovarian cancer who previously have had no identified genetic cause for their family's disease; this might be it for them,' said Joanne Weidhaas, associate professor of therapeutic radiology, researcher for the Yale Cancer Center and co-senior author of the study. “Our findings support that the KRAS-variant is a new genetic marker of ovarian cancer risk.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs